MUSE Cells: Real Science vs. False Promises in Regenerative Medicine

MUSE cells have gained attention for their regenerative potential without tumor risk, unlike other pluripotent stem cells. This newsletter offers a critical review of their biology, clinical evidence, and the misuse of the MUSE label in unregulated commercial practices. Drawing on scientific publications and clinical trials, it warns against fraudulent therapies that falsely claim MUSE status. The article aims to guide physicians and clinics toward an ethical, responsible, and evidence-based approach to regenerative treatments.

In the field of regenerative medicine, few cells have generated as much expectation—and confusion—as MUSE cells (Multilineage-differentiating Stress-Enduring cells). These cells represent a promising advancement in the development of safe regenerative therapies. Unlike embryonic stem cells or iPSCs, MUSE cells combine functional pluripotency without tumorigenicity, opening clinically relevant possibilities without ethical conflicts.

However, in countries such as Mexico, there has been a surge of cell therapies labeled as “MUSE” that do not meet scientific or regulatory criteria. These practices have emerged as opportunistic responses to growing medical and social interest in innovative therapies, yet they lack molecular characterization, functional validation, and quality control—posing serious risks to patients and the credibility of the medical field.

This bulletin aims to provide a clear, well-grounded review to help physicians and healthcare professionals distinguish between legitimate evidence and pseudoscience.

What are MUSE cells?

Discovered in 2010 by Dr. Mari Dezawa’s team (Tohoku University, Japan), MUSE cells are a rare subpopulation of adult stem cells found in bone marrow, adipose tissue, skin, and peripheral blood. They are characterized by:

– Surviving extreme stress conditions.
– Expressing pluripotency markers (SSEA-3+, OCT4, NANOG, TERT).
– Differentiating into ectodermal, mesodermal, and endodermal lineages.
– Not forming teratomas in vivo.
– Naturally migrating to damaged tissues and functionally integrating.

Understanding their isolation is essential to avoid misapplication in clinical settings.

How are they correctly isolated and identified?

MUSE cells cannot be obtained simply by centrifuging tissue or using generic commercial kits. Their isolation requires:

– Culturing under stress conditions (serum-free, hypoxia), eliminating other cells.
– Enrichment by flow cytometry or magnetic separation specifically for the SSEA-3+ marker.
(These are advanced lab techniques used to select cells with specific features.)
– Molecular and functional validation:
– Expression of OCT4, NANOG, TERT.
– In vitro trilineage differentiation.
– Directed integration in animal models.
– Confirmation of non-tumorigenicity.

MUSE vs MSCs vs iPSCs

The following simplified comparison highlights the main differences between MUSE cells, traditional MSCs, and iPSCs.

Current state of evidence

Neurology
Phase 1/2 clinical trial in Japan (Yamauchi et al., 2022) with intravenous infusion of allogenic MUSE cells in stroke patients: functional improvement without serious adverse events.

Cardiology
In animal models of infarction: reduction of infarct size and improved ventricular function.

Pulmonology and Hepatology
In pulmonary fibrosis and toxic hepatitis, MUSE cells showed functional integration and tissue damage reduction.

While results are promising, most applications are still in early clinical or preclinical validation stages.

Risks of malpractice

In Mexico and Latin America, several clinics have been documented:

– Labeling MSC populations without SSEA-3+ as “MUSE”.
– Offering cell therapies without functional validation.
– Selling products without health licenses or biosafety protocols.

Clinical and legal consequences:
– Risk to patient health (ineffectiveness, immune reactions).
– Regulatory sanctions and loss of medical credibility.
– Reputational damage to the regenerative medicine field.

Clinical recommendations

As responsible professionals:
– Request technical documentation from providers: SSEA-3+ characterization, OCT4, trilineage differentiation.
– Verify compliance with GMP standards and regulatory approvals.
– Review published evidence and ongoing clinical trials.
– Educate patients: not all “stem cells” are the same, and not all are validated.
– Report unethical practices or misleading advertising to health authorities.

Conclusion

MUSE cells are a genuine scientific breakthrough with solid foundations and a clinical path that must be followed rigorously. Their responsible use could transform areas such as neurology, cardiology, and chronic diseases, but unsound commercial exploitation endangers that promise.

As a medical community, we have the responsibility to distinguish between innovation and unsupported solutions. Let’s not confuse marketing with science. Regenerative medicine deserves integrity.

References

Dezawa M et al. PNAS, 2010.
Wakao S et al. Cell Stem Cell, 2012.
Yamauchi T et al. Stem Cells Transl Med, 2022.
Kuroda Y et al. Cell Transplant, 2015.
Katagiri H et al. Nat Commun, 2016.
ClinicalTrials.gov ID: NCT02284092
Wakao S et al. Stem Cells Int, 2020.

Want to learn more?

• Request the infographic version of this newsletter to share with colleagues.
• If you are a physician or clinic director interested in cellular therapies, we can help you validate providers and products based on science and regulatory compliance.

Author: Jose Luis Flores Sevilla, MSc. PhD. Molecular Biomedicine.